BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 27115465)

  • 1. Expression of the chemokine CXCL14 in the tumour stroma is an independent marker of survival in breast cancer.
    Sjöberg E; Augsten M; Bergh J; Jirström K; Östman A
    Br J Cancer; 2016 May; 114(10):1117-24. PubMed ID: 27115465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of stromal and epithelial periostin expression in human breast cancer: correlation with clinical pathological features and mortality outcome.
    Nuzzo PV; Rubagotti A; Zinoli L; Salvi S; Boccardo S; Boccardo F
    BMC Cancer; 2016 Feb; 16():95. PubMed ID: 26872609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of CXCL14 and its anticancer role in breast cancer.
    Gu XL; Ou ZL; Lin FJ; Yang XL; Luo JM; Shen ZZ; Shao ZM
    Breast Cancer Res Treat; 2012 Oct; 135(3):725-35. PubMed ID: 22910931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
    De Brot M; Rocha RM; Soares FA; Gobbi H
    Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXCL14 and NOS1 expression in specimens from patients with stage I-IIIA nonsmall cell lung cancer after curative resection.
    Ji X; Shen Z; Zhao B; Yuan X; Zhu X
    Medicine (Baltimore); 2018 Mar; 97(10):e0101. PubMed ID: 29517684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel ACKR2-Dependent Role of Fibroblast-Derived CXCL14 in Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer.
    Sjöberg E; Meyrath M; Milde L; Herrera M; Lövrot J; Hägerstrand D; Frings O; Bartish M; Rolny C; Sonnhammer E; Chevigné A; Augsten M; Östman A
    Clin Cancer Res; 2019 Jun; 25(12):3702-3717. PubMed ID: 30850359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asporin is a stromally expressed marker associated with prostate cancer progression.
    Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
    Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-β signaling proteins.
    Zou A; Lambert D; Yeh H; Yasukawa K; Behbod F; Fan F; Cheng N
    BMC Cancer; 2014 Oct; 14():781. PubMed ID: 25344051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers.
    Bradford JR; Wappett M; Beran G; Logie A; Delpuech O; Brown H; Boros J; Camp NJ; McEwen R; Mazzola AM; D'Cruz C; Barry ST
    Oncotarget; 2016 Apr; 7(15):20773-87. PubMed ID: 26980748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of CD10 expression in clinical outcome of invasive breast carcinoma.
    Vo TN; Mekata E; Umeda T; Abe H; Kawai Y; Mori T; Kubota Y; Shiomi H; Naka S; Shimizu T; Murata S; Yamamoto H; Ishida M; Tani T
    Breast Cancer; 2015 Mar; 22(2):117-28. PubMed ID: 23575921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of epithelial-mesenchymal transition proteins Twist and Foxc2 in phyllodes tumours of the breast.
    Lim JC; Koh VC; Tan JS; Tan WJ; Thike AA; Tan PH
    Breast Cancer Res Treat; 2015 Feb; 150(1):19-29. PubMed ID: 25677742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-6 receptor in spindle-shaped stromal cells, a prognostic determinant of early breast cancer.
    Labovsky V; Martinez LM; Calcagno ML; Davies KM; García-Rivello H; Wernicke A; Feldman L; Giorello MB; Matas A; Borzone FR; Howard SC; Chasseing NA
    Tumour Biol; 2016 Oct; 37(10):13377-13384. PubMed ID: 27460086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stromal IGF-II messenger RNA in breast cancer: relationship with progesterone receptor expressed by malignant epithelial cells.
    Giani C; Pinchera A; Rasmussen A; Fierabracci P; Bonacci R; Campini D; Bevilacqua G; Trock B; Lippman ME; Cullen KJ
    J Endocrinol Invest; 1998 Mar; 21(3):160-5. PubMed ID: 9591211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic stromal gene signatures in breast cancer.
    Winslow S; Leandersson K; Edsjö A; Larsson C
    Breast Cancer Res; 2015 Feb; 17(1):23. PubMed ID: 25848820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated S100A8 protein expression in breast cancer cells and breast tumor stroma is prognostic of poor disease outcome.
    Miller P; Kidwell KM; Thomas D; Sabel M; Rae JM; Hayes DF; Hudson BI; El-Ashry D; Lippman ME
    Breast Cancer Res Treat; 2017 Nov; 166(1):85-94. PubMed ID: 28717852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of TRAIL-R3 and CCR-2 expression in tumor epithelial cells of patients with early breast cancer.
    Labovsky V; Martinez LM; Davies KM; de Luján Calcagno M; García-Rivello H; Wernicke A; Feldman L; Matas A; Giorello MB; Borzone FR; Choi H; Howard SC; Chasseing NA
    BMC Cancer; 2017 Apr; 17(1):280. PubMed ID: 28420351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
    Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P
    Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A shift from membranous and stromal syndecan-1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer.
    Kind S; Jaretzke A; Büscheck F; Möller K; Dum D; Höflmayer D; Hinsch A; Weidemann S; Fraune C; Möller-Koop C; Hube-Magg C; Simon R; Wilczak W; Lebok P; Witzel I; Müller V; Schmalfeldt B; Paluchowski P; Wilke C; Heilenkötter U; von Leffern I; Krech T; Krech RH; von der Assen A; Bawahab AA; Burandt E
    Mol Carcinog; 2019 Dec; 58(12):2306-2315. PubMed ID: 31545001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression.
    Kleer CG; Bloushtain-Qimron N; Chen YH; Carrasco D; Hu M; Yao J; Kraeft SK; Collins LC; Sabel MS; Argani P; Gelman R; Schnitt SJ; Krop IE; Polyak K
    Clin Cancer Res; 2008 Sep; 14(17):5357-67. PubMed ID: 18765527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival.
    Mirisola V; Zuccarino A; Bachmeier BE; Sormani MP; Falter J; Nerlich A; Pfeffer U
    Eur J Cancer; 2009 Sep; 45(14):2579-87. PubMed ID: 19646861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.